Q2 2023

Filed Aug 10, 2023 · 10-Q · 41 days after period end · 0001401914-23-000045

Q2 2023 · 10-Q

Revenue

$0.00

−100.0% vs Q2 2022

Net Income

-$8.76M

N/M vs Q2 2022

EPS Diluted

-$1.22

— vs Q2 2022

Operating Income-$8,989,356N/M

Operating Cash Flow

Same quarter

Metric	Q2 2023	Q2 2022	Q2 2021	Q2 2020
Revenue	$0.00	$10.00M	$0.00	—
Net Income	-$8.76M	$414.00K	-$9.16M	-$7.12M
EPS Diluted	-$1.22	$0.00	-$0.18	-$0.27

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Dare Bioscience, Inc. · CIK 1401914 · Engraved from SEC EDGAR